Jean-Claude Kyrillos net worth and biography

Jean-Claude Kyrillos Biography and Net Worth

Executive Vice President and Chief Operating Officer of Tandem Diabetes Care

Jean-Claude “JC” Kyrillos has served as our Executive Vice President and Chief Operating Officer since June 2024 and is responsible for the Company’s manufacturing operations, supply chain, quality, regulatory and program management functions. Mr. Kyrillos has more than 20 years of executive leadership experience in the medical device and digital health industries. Before joining our Company, he served in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently as President of Diagnostics and Digital Solutions. Prior to that, Mr. Kyrillos was Senior Vice President and General Manager at Qualcomm Life, the healthcare division at Qualcomm, from May 2016 to February 2019. Before his time at Qualcomm, Mr. Kyrillos served as Senior Vice President and General Manager of infusion solutions at Becton Dickinson from August 2011 to May 2016. Prior to that, Mr. Kyrillos held leadership positions at ResMed Inc. from January 2008 to August 2011, most recently serving as President of ResMed Ventures and Initiatives. Mr. Kyrillos has served as an independent board director of San Deigo Blood Bank since January 2016 and as Chair from January 2020 to December 2022. Mr. Kyrillos received a BA with Honors in History from Colgate University and a MBA from Harvard Business School.

What is Jean-Claude Kyrillos' net worth?: The estimated net worth of Jean-Claude Kyrillos is at least $207,177.08 as of March 7th, 2025. Mr. Kyrillos owns 10,538 shares of Tandem Diabetes Care stock worth more than $207,177 as of March 26th. This net worth estimate does not reflect any other investments that Mr. Kyrillos may own. Learn More about Jean-Claude Kyrillos' net worth.
How do I contact Jean-Claude Kyrillos?: The corporate mailing address for Mr. Kyrillos and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at smorrison@tandemdiabetes.com. Learn More on Jean-Claude Kyrillos' contact information.
Has Jean-Claude Kyrillos been buying or selling shares of Tandem Diabetes Care?: During the last quarter, Jean-Claude Kyrillos has bought $190,948.56 in shares of Tandem Diabetes Care stock. Most recently, on Friday, March 7th, Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock. The stock was acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. Learn More on Jean-Claude Kyrillos' trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes Dick Allen (Director), David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), Shannon Hansen (Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary), Jean-Claude Kyrillos (Executive Vice President and Chief Operating Officer), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Mark Novara (Executive Vice President and Chief Commercial Officer), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 2 times. They purchased a total of 11,070 shares worth more than $203,312.24. In the last twelve months, insiders at the medical device company sold shares 3 times. They sold a total of 25,000 shares worth more than $858,400.00. The most recent insider tranaction occured on March, 7th when COO Jean-Claude Kyrillos bought 10,538 shares worth more than $190,948.56. Insiders at Tandem Diabetes Care own 2.2% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 3/7/2025.

Jean-Claude Kyrillos Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/7/2025	Buy	10,538	$18.12	$190,948.56	10,538

Jean-Claude Kyrillos Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $19.66

$19.12

$20.30

50 Day Range

MA: $29.08

$17.89

$37.53

2 Week Range

Now: $19.66

$17.64

$53.69

Volume

976,014 shs

Average Volume

1,463,605 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45